These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10026883)

  • 1. Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.
    Ostrand-Rosenberg S; Pulaski BA; Armstrong TD; Clements VK
    Adv Exp Med Biol; 1998; 451():259-64. PubMed ID: 10026883
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
    Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
    Pulaski BA; Ostrand-Rosenberg S
    Cancer Res; 1998 Apr; 58(7):1486-93. PubMed ID: 9537252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
    Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
    Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
    Hurwitz AA; Yu TF; Leach DR; Allison JP
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10067-71. PubMed ID: 9707601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
    Baskar S; Ostrand-Rosenberg S; Nabavi N; Nadler LM; Freeman GJ; Glimcher LH
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5687-90. PubMed ID: 7685909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.
    Wu RS; Kobie JJ; Besselsen DG; Fong TC; Mack VD; McEarchern JA; Akporiaye ET
    Cancer Immunol Immunother; 2001 Jul; 50(5):229-40. PubMed ID: 11499806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous expression of allogenic class II MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity.
    Jang YJ; Nam SY; Kim MS; Seong RH; Park YS; Chung YH; Chung HY
    Mol Cells; 2002 Feb; 13(1):130-6. PubMed ID: 11911464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.
    Chan K; Lee DJ; Schubert A; Tang CM; Crain B; Schoenberger SP; Corr M
    J Immunol; 2001 Mar; 166(5):3061-6. PubMed ID: 11207256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An epigenetically altered tumor cell vaccine.
    Khan AN; Magner WJ; Tomasi TB
    Cancer Immunol Immunother; 2004 Aug; 53(8):748-54. PubMed ID: 14997346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector.
    Döhring C; Angman L; Spagnoli G; Lanzavecchia A
    Int J Cancer; 1994 Jun; 57(5):754-9. PubMed ID: 7515023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/BB1 and upregulation of major histocompatibility complex class II molecules.
    Kosco-Vilbois MH; Gray D; Scheidegger D; Julius M
    J Exp Med; 1993 Dec; 178(6):2055-66. PubMed ID: 7504055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-based vaccines for the stimulation of immunity to metastatic cancers.
    Ostrand-Rosenberg S; Pulaski BA; Clements VK; Qi L; Pipeling MR; Hanyok LA
    Immunol Rev; 1999 Aug; 170():101-14. PubMed ID: 10566145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo inhibition of anti-Thy-1 response by monoclonal antibody to the A molecules of the responder.
    Zaleski MB; Gorzynski TJ; Quackenbush LJ; Dowjat WK
    Immunogenetics; 1985; 22(6):673-7. PubMed ID: 2867032
    [No Abstract]   [Full Text] [Related]  

  • 18. Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination.
    Kerkmann-Tucek A; Banat GA; Cochlovius B; Zöller M
    Int J Cancer; 1998 Jul; 77(1):114-22. PubMed ID: 9639402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of antigen processing and major histocompatibility complex class II-restricted presentation.
    Lich JD; Blum JS
    Methods Mol Biol; 2001; 156():49-56. PubMed ID: 11068749
    [No Abstract]   [Full Text] [Related]  

  • 20. Antigen processing and CD4+ T cell depletion in AIDS.
    Germain RN
    Cell; 1988 Aug; 54(4):441-4. PubMed ID: 2969773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.